Celsion enters ThermoDox supply agreement with Hisun Pharma

ThermoDox is Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, used for the treatment of various cancers.

The agreement will provide Celsion with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for China.

Celsion’s president and chief executive officer Michael H. Tardugno said the partnership with Hisun supports ThermoDox drug approval and product launch both in China and internationally.

"In addition, this partnership brings a timely investment for the expansion of our manufacturing and CMC efforts, accelerating our drug development program," H. Tardugno added.

The efficacy of ThermoDox in combination with Radio frequency ablation (RFA) has been evaluated in the Phase III HEAT study.